Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale

Rhea-AI Filing Summary

Viridian Therapeutics, Inc. insider Jennifer Tousignant, the company’s Chief Legal Officer, reported a transaction in the company’s common stock. On 12/31/2025, she disposed of 2,272 shares of Viridian common stock at a price of $31.16 per share, coded as a sale. Following this transaction, the filing lists her as beneficially owning 0 shares directly. The footnote explains that the reported shares consist of stock purchased under Viridian’s employee stock purchase plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tousignant Jennifer

(Last) (First) (Middle)

C/O VIRIDIAN THERAPEUTICS, INC.

221 CRESCENT STREET, SUITE 103A

(Street)

WALTHAM MA 02453

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.\DE [ VRDN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/31/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/31/2025		S		2,272(1)	D	$31.16	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of shares purchased under the Issuer's employee stock purchase plan.

	/s/ Jennifer Tousignant	01/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Viridian Therapeutics (VRDN) report in this filing?

The filing reports that Chief Legal Officer Jennifer Tousignant disposed of 2,272 shares of Viridian Therapeutics common stock on 12/31/2025, coded as a sale.

At what price were the Viridian Therapeutics (VRDN) shares transacted?

The transaction involved Viridian Therapeutics common stock at a reported price of $31.16 per share.

How many Viridian Therapeutics (VRDN) shares does the insider report owning after the transaction?

After the reported transaction, the Form 4 shows that the reporting person beneficially owns 0 shares of Viridian Therapeutics common stock directly.

What is the role of the reporting person at Viridian Therapeutics (VRDN)?

The reporting person, Jennifer Tousignant, is listed as an Officer of Viridian Therapeutics, serving as the company’s Chief Legal Officer.

What type of Viridian Therapeutics (VRDN) shares were involved in this insider transaction?

The filing notes that the 2,272 shares involved in the transaction consist of shares purchased under Viridian Therapeutics’ employee stock purchase plan.

Does this Viridian Therapeutics (VRDN) insider filing report any derivative securities?

The section for derivative securities is present, but in the provided excerpt there are no derivative transactions reported with specific amounts or dates.